Morovan Gel Nail Polish Remover Recalled for Prohibited Methylene Chloride and Chloroform
Morovan is recalling approximately 4,000 units of its Gel Nail Polish Remover (15ml) after testing revealed the presence of methylene chloride and chloroform—both substances prohibited in cosmetic formulations under FDA regulations. Methylene chloride has been shown to cause cancer in animals and is not permitted at any level in cosmetics. The affected product was sold on Amazon.com from August 2025 through January 2026. Consumers who purchased the product should immediately stop use and dispose of it properly.
Physio-Control/Stryker France DAE Electrode Kit Recall - Infant/Child Use
ANSM reports a safety recall by Physio-Control/Stryker France SAS for infant and child DAE (automated external defibrillator) electrode kits. Reference numbers R2607604/R2610482. Affected lots expired between August 2025 and January 2026. Hospital pharmacies, distributors, and operators holding these products should contact Stryker France directly for guidance.
Da Vinci X Xi Cannula Screw Safety Notice - Intuitive Surgical
ANSM has published a safety notice (Reference R2606328) informing French healthcare facilities about a safety action by Intuitive Surgical regarding cannula support screws on da Vinci X and Xi robotic surgical systems. Users have received direct communication from the manufacturer. Healthcare facilities with these systems should review the attached manufacturer letter for specific guidance.
Compound Emulsion Injection for Nausea and Vomiting
The USPTO published patent application US20260097042A1 for a compound emulsion combining aprepitant and palonosetron hydrochloride for injection. The formulation claims improved stability and enhanced patient adherence in preventing and treating nausea and vomiting. The application was filed on May 30, 2025.
Compositions and Methods for IV Administration of ABDNAZ for Cancer Treatment
USPTO published patent application US20260097013A1 for compositions and methods for intravenous administration of ABDNAZ (2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone) for cancer treatment. The application, filed on 2025-06-11, covers formulations containing autologous whole blood and ABDNAZ for rapid IV infusion. Inventors: Bryan T. Oronsky, Jan Scicinski, and Scott Caroen.
Field Safety Notices: 6 to 10 April 2026
MHRA published a weekly compilation of 15 Field Safety Notices (FSNs) for medical devices issued 6-10 April 2026. FSNs cover devices including gastric balloons, surgical systems, intraocular lenses, CT systems, and diagnostic equipment. MHRA notes it publishes FSNs for information only, and recipients must act on FSNs received directly from manufacturers.
Epoxytiglienone Compounds for Disrupting Gram-negative Bacterial Biofilms
The USPTO has published patent application US20260097011A1 for epoxytiglienone compounds designed to disrupt biofilms comprising Gram-negative bacteria. The application covers methods of dispersing established biofilms through localized administration, including topical or injection delivery, as well as methods for preventing biofilm formation on medical devices. Inventors include David William Thomas, Paul Warren Reddell, Glen Mathew Boyle, and others. The application was filed on December 2, 2025.
Compounds and Combinations Thereof for Treating Neurological and Psychiatric Conditions
The USPTO published patent application US20260097006A1 by inventor Herriot Tabuteau, filed September 4, 2025, covering compounds and combinations containing dextromethorphan for treating neurological and psychiatric conditions. The application discloses dosage forms and drug delivery systems typically combined with antidepressants such as bupropion. This publication makes the application publicly available for review and potential opposition.
Cell-Free Vascular Grafts and Graft Materials for Cellular Recruitment
USPTO published patent application US20260097149A1 for cell-free vascular graft materials incorporating bispecific binding partners with luminal and cellular binding domains for cellular recruitment. The application, filed June 26, 2023 under Application No. 18880781, covers fusion peptides with heparin and monocyte binding domains, methods of making the grafts, and methods of use including A-TEV technology.
Method for Treating Neurodegenerative Diseases with Polymer-Flavonoid Conjugates
The USPTO published patent application US20260097130A1 for a method of treating neurodegenerative diseases using polymer-flavonoid conjugates. Inventors Chun-Ting Cheng, Kuo-Liang Hou, and Pauline Ying Lau claim compositions that enable therapeutic materials to cross the blood-brain barrier. The application covers treatment of Alzheimer's disease, Parkinson's disease, Lewy body dementia, and Huntington's disease using the disclosed nanocomplex formulations.
Silver Nanoparticle Treatment for Carious Lesions, 3-5 Weeks
The USPTO published patent application US20260096959A1 filed by R.M CREIGHTON DENTAL PTY LTD for a method of treating carious lesions using silver nanoparticles. The treatment involves applying a first dental solution containing a silver salt followed by a second dental solution containing a reducing agent within less than 10 minutes. The lesion consolidates over 3-5 weeks to form a matte black crust containing nanoparticles. Invented by Graham G. Craig.
Anhydrous Powder Hair Lightening Suspension
USPTO published patent application US20260096960A1 by inventor David Erlingheuser for an anhydrous powder hair lightening suspension composition on April 9, 2026. The composition comprises 5-60% non-volatile oil, 3-30% petrolatum, 0.05-5% fumed silica, 1-70% persulfate salt, and 0% microplastics. This publication establishes a priority date and provides public notice of the pending patent claims.
Circular DNA Purification Using Nanoclays
USPTO published patent application US20260098252A1 by Texas State University (filed October 3, 2025) disclosing a method of purifying circular DNA from samples using nanoclays that preferentially adsorb contaminants including non-circular DNA, RNA, proteins, and endotoxins while leaving circular DNA unbound. The elution-free method separates nanoclay-contaminant complexes from the enriched circular DNA fraction. The invention also covers compositions and systems for such purification and methods of refining nanoclays for the purification process.
Nucleic Acid Extraction Methods, Waters Corp, 9th Apr
Nucleic Acid Extraction Methods, Waters Corp, 9th Apr
Lysis Vessel with Dual Membranes and Non-Magnetic Beads for On-Board Cell Lysis
USPTO published patent application US20260098253A1 assigned to Gen-Probe Incorporated. The application covers a lysis vessel for performing cell lysis that includes a laterally extending member and sleeve with dual porous membranes, non-magnetic beads, and at least one magnetic element contained within a lysis chamber. Filing date was December 11, 2025, under application number 19416385.
Methods of Improving Unique Molecular Index Ligation Efficiency
Illumina, Inc. has filed a patent application (US20260098256A1) for methods and adapter pools that improve unique molecular index (UMI) ligation efficiency in nucleic acid sequencing applications. The invention enables more accurate quantification of polynucleotide fragments by providing UMIs that are uniquely associable with individual fragments. The application was published April 9, 2026, with a filing date of December 12, 2025. Biotechnology companies developing next-generation sequencing technologies may need to review this application to assess potential impacts on their IP strategies or freedom-to-operate analysis. Researchers and diagnostic developers using UMI-based sequencing methods should monitor this and related patent activity for potential licensing implications.
BEST1 Vectors for Retinal Dystrophy Treatment
The USPTO published patent application US20260098277A1 covering BEST1-targeted expression constructs, nucleic acid vectors, and pharmaceutical compositions for treating BEST1-associated retinal dystrophies including autosomal dominant bestrophinopathies. The application includes BEST1-targeted shRNAs, BEST1 coding sequences, promoters, and regulatory elements designed to improve functional BEST1 expression in subjects with BEST1 mutations. This published application represents an early-stage intellectual property filing with no granted rights or compliance obligations established.
CO2 Conversion to C2+ Chemicals via Electrochemical and Microbial Process
USPTO published patent application US20260098282A1 disclosing a method for converting carbon dioxide to higher value C2+ chemicals using an electrochemical cell with a carbon dioxide reducing catalyst combined with microbial conversion. The application was filed on September 23, 2023, by inventors Peng Zhang, Kainan Chen, Joshua Shuhua Yuan, and Susie Y. Dai. The publication makes the application publicly available but does not constitute a granted patent.
In Vitro Bioproduction of Polyhydroxyalkanoate Monomers
USPTO published patent application US20260098283A1 by inventor Stephen Quirk for an enzymatic process to produce homogeneous chain length polyhydroxyalkanoate (PHA) monomers and polymers with chain lengths of at least eight carbons from long-chain fatty acids. The process enables specific, controlled production of PHA materials through in vitro enzyme contact with long-chain fatty acid precursors.
KWS SAAT Immature Inflorescence Meristem Gene Editing
KWS SAAT SE & Co. KGaA has published a patent application (US20260098273A1) for a method of plant genome modification targeting immature inflorescence meristem (IIM) cells. The method uses genome editing systems with optional regeneration boosters, delivered via particle bombardment, to modify genomic target sites in plant cells and regenerate modified plant tissues, organs, or seeds.
Cell-Free PPi-Driven ATP Regeneration Platform Patent
Cell-Free PPi-Driven ATP Regeneration Platform Patent
Methods for Assaying Enriched Nucleic Acids Using Complementary Probes
The USPTO published patent application US20260098304A1 covering methods for assaying enriched nucleic acids using probes with sequences complementary to RNA expression products to determine expression levels of multiple genes. The application was filed on October 3, 2024 by inventors including Charles M. Perou, Joel S. Parker, and others. The claimed methods enable enrichment of nucleic acid molecules for gene expression analysis in biological samples.
Protein Evolution System With DNA Synthesis, Microfluidics
The USPTO published patent application US20260098257A1 covering systems, methods, and kits for rapid protein evolution. The application (No. 19271120, filed July 16, 2025) names five inventors and describes a system combining DNA synthesis, microfluidic devices with sequestration pens, and a computing component for iterative protein optimization. The technology enables cell-free protein expression and assay-based evaluation of protein variants.
DNA Origami Nanostructures for Molecular Data Storage Patent Application
USPTO published patent application US20260098258A1 on April 9, 2026, disclosing compositions and methods using DNA origami principles to package and archive data stored in multiple indexed DNA oligonucleotides. The application (No. 19319178, filed September 4, 2025) covers DNA origami (DNAO) nanostructures enabling selective physical data access and retrieval from a molecular pool.
Root-Mediated Uptake of Guide RNA for Genomic Editing of a Plant
USPTO published patent application US20260098274A1 by Inari Agriculture Technology disclosing methods for editing plant genomes by delivering guide RNA to plant roots for CRISPR-Cas editing in meristems. Inventors include Aran McCay, Michael Lee Nuccio, and Palak Kathiria. The filing date was March 7, 2024.
UORF Editing to Improve Crop Plant Agronomic Traits
USPTO published patent application US20260098275A1 assigned to Inari Agriculture Technology, Inc., disclosing methods of improving agronomic traits in crop plants through editing sequences within the 5' untranslated region (5' UTR) of plant genomes. The application names Ross Everett Altman, Malachy T. Campbell, Karl Anton Grothe Kremling, and Ruijuan Li as inventors. Filing date was April 10, 2024.
CHIMERIC ANTIGEN RECEPTOR SPACERS
The USPTO published Lyell Immunopharma's patent application US20260098075A1 for chimeric antigen receptors (CARs) incorporating immunoglobulin-derived spacers, such as hinge or loop regions, designed to enhance cytokine release compared to CARs with non-Ig-derived spacers. The spacers may be derived from human immunoglobulins (IgAQ1, IgA2, IgD, IgE, IgG1-4, IgM) or non-human sources (e.g., mouse IgG2A), and may be configured as modular constructs combining multiple Ig hinges or fragments thereof. Filed September 8, 2025.
Cancer Therapy Delivery System with Tumbling Container for Suspension Generation
USPTO published patent application US20260096951A1 for a cancer therapy delivery system featuring a tumbler vial for generating therapeutic microsphere suspensions. The system includes a rotation mechanism, fluid inlet and outlet lines configured to twist during rotation, and a cap occluding the vial end. The application was filed on October 9, 2025.
Cholesterol Efflux Modulation Compositions and Methods - US20260097053A1
USPTO published patent application US20260097053A1 for compositions and methods modulating cholesterol efflux via ABCA1 for treating atherosclerosis and related diseases. Invented by Kailash Gulshan, the application claims PIP2 compositions affecting ABCA1 levels and promoting reverse cholesterol transport (RCT) to reduce cholesterol and atherosclerosis. This is a patent application publication establishing a filing date, not a granted patent.
Novel Formulations and Vehicles for DAPTZ Compounds Including Methylene Blue
USPTO published patent application US20260097043A1 assigned to WisTa Laboratories Ltd., covering novel oral pharmaceutical formulations of diaminophenothiazine (DAPTZ) compounds such as methylene blue. The application discloses gastro-retentive platforms including film-coated solid tablets and buoyant self-orientating capsules with sustained-release coatings. The filing was submitted on September 20, 2023, under application number 19113777.
Solanum Lycopersicum Plants Having Improved Tobamovirus Resistance
The USPTO published patent application US20260096533A1 granting protection for hybrid Solanum lycopersicum tomato plants containing the Rug-1 resistance gene that confers Tomato Brown Rugose Fruit Virus (ToBRFV) tolerance/resistance. The patent covers the plant, seeds, fruits, plant parts, and methods for identifying, selecting, and producing ToBRFV-resistant tomato plants using the specified genetic marker.
Implantable Device for Administering a Therapeutic Agent
USPTO published patent application US20260096984A1 filed by inventors Harsh Patel and Jeffrey Haley on October 3, 2025. The application covers an implantable device for delivering therapeutic agents, featuring a core polymer matrix with hydrophobic poly ortho ester (POE) polymer having a glass transition temperature between -20°C and 40°C. The device is designed for controlled therapeutic agent release in vivo.
Understanding Responsibilities When Importing, Compounding and Supplying Unapproved Peptide Products
TGA has published a safety advisory warning of rising import, supply, compounding and advertising of unapproved peptide products in Australia. Products containing BPC-157, GHK-Cu, TB-500, retatrutide, and CJC-1295 are specifically identified as unapproved goods not evaluated for safety, quality, or effectiveness. The TGA states it is actively monitoring this issue from both safety and law enforcement perspectives and reminds affected parties of their obligations under the Therapeutic Goods Act 1989.
Biodegradable Microcapsules and Method for Their Preparation
USPTO published patent application US20260096991A1 for biodegradable microcapsules and methods for their preparation. The application relates to microcapsule compositions for drug delivery, classified under A61K. Filing date was September 7, 2023, with nine listed inventors.
Solid Dispersions Having Stabilized Emulsion Particles Patent Application
USPTO published patent application US20260096994A1 for solid dispersion compositions containing active pharmaceutical ingredients and dispersion carriers. The application covers methods of dissolving API with carriers, combining with anti-solvent containing surfactant to form emulsions, and removing solvent to achieve predetermined particle size ranges. The application notably includes Compound (1) (zongertinib).
Teardrop Effervescent Tablet, Rapid Dissolution, Oral Drug Delivery
USPTO published patent application US20260096993A1 for a teardrop-shaped effervescent tablet designed for rapid dissolution oral drug delivery. The application (No. 18909065) was filed on October 8, 2024 and published April 9, 2026. Inventors Philip Mackenzie and Dan Aziz disclose a tablet with asymmetric geometry and cupped surfaces engineered to accelerate dissolution rates and improve bioavailability of active ingredients.
Polymeric Delivery System Patent for Biologics
USPTO published patent application US20260096990A1 for a polymeric delivery system designed to deliver biologic therapeutics to cells. The invention covers polyplexes composed of charged polyesters and biologics, as well as self-assembled particles with block copolymers. The application was filed on December 12, 2025, by inventors Jeremy J. Harris, Scott Radzinski, Brian Ginn, Peter D. Gabriele, and Benjamin Roadarmel.
CD19/CD22 CAR T Cell Treatment for High-Risk Pediatric Acute Lymphoblastic Leukemia
The USPTO published patent application US20260097122A1 for CD19/CD22 chimeric antigen receptor (CAR) T-cell products and methods for treating high-risk or relapsed CD19+ or CD22+ haematological malignancies, specifically pediatric acute lymphoblastic leukemia. The application was filed on May 10, 2023, under application number 18862269. Inventors include Martin Pulé, Persis Amrolia, and Sara Ghorashian.
Epigenetic Editing Tool for Targeting Hepatitis B Virus Gene
USPTO published patent application US20260097133A1 for an epigenetic editing tool targeting hepatitis B virus genes, filed by inventors Wenbo Peng, Junzheng Zhao, Shaoshuai Mao, Leilei Wu, Di Sun, Ruimin Lv, Ying Zang, and Junjian Liu on December 4, 2025. The application covers compositions and methods for epigenetic modification of HBV genes for therapeutic use in biomedicine.
Fluorescent Probe Compounds for Tumor-Targeted Imaging and Synthesis Methods
USPTO published patent application US20260097137A1 by Hebei Medical University for fluorescent probe compounds utilizing a pyrrolo[2,3-d]pyrimidine core structure conjugated to a fluorescent dye for tumor-targeted imaging. The probes demonstrate high affinity and selectivity for tumor cells, rapid clearance from normal tissues, and prolonged retention at tumor sites. The invention enables in vitro and in vivo tracking, receptor affinity studies, and intraoperative navigation applications.
Rapid Conjugate Vaccine Manufacturing Method, Inventprise
Rapid Conjugate Vaccine Manufacturing Method, Inventprise
Oncolytic Vaccinia Viruses and Recombinant Viruses and Methods of Use Thereof
The USPTO published patent application US20260097116A1 by ViroMissile, Inc. covering clonal strains of vaccinia virus engineered as oncolytic virus therapies for treating cancer. The application includes claims for recombinant vaccinia viruses with inactivating mutations and heterologous gene products, pharmaceutical compositions, and methods of use for anti-tumor therapy.
GIP/GLP-1 Dual Agonist Formulations for Metabolic and Liver Disorders
The USPTO published patent application US20260097126A1 disclosing pharmaceutical formulations of small molecule GIP/GLP-1 dual receptor agonists for treating metabolic and liver disorders. The application (No. 18995773) was filed on July 18, 2023, by inventors Brian Lian, Geoffrey E. Barker, Maureen Barnes, Brahmachary Enugurthi, and Jake Gonzalez. The formulations include compounds classified under CPC codes A61K 47/548, A61K 9/0019, and others, with therapeutic applications targeting A61P 3/06 (metabolic disorders).
Self-Circularized RNA Preparation Method, Apr 09
Self-Circularized RNA Preparation Method, Apr 09
Exon 44 Duchenne Muscular Dystrophy Cyclic Peptide Antisense
The USPTO published patent application US20260098262A9 covering compositions comprising a cyclic peptide and an antisense compound targeting exon 44 of the DMD gene for Duchenne Muscular Dystrophy treatment. The application was filed on August 30, 2022, under application number 18688083, listing nine inventors including Xiang Li, Ziqing Qian, and others. No compliance obligations or deadlines are associated with this publication. This patent application publication represents a formal administrative record from the USPTO but does not create any regulatory obligations or deadlines for affected parties. Pharmaceutical and biotechnology companies developing exon-skipping therapies for DMD may wish to review the claims for potential freedom-to-operate implications.
Modified Double-Stranded RNA Agents Inhibit Gene Expression
USPTO published patent application US20260098263A1 for modified double-stranded RNA (dsRNA) agents capable of inhibiting gene expression. The application was published April 9, 2026, with inventors Martin MAIER, Don FOSTER, Stuart MILSTEIN, Satya KUCHIMANCHI, Vasant JADHAV, Kallanthottathil RAJEEV, Muthiah MANOHARAN, and Rubina PARMAR. The dsRNA agents contain thermally destabilizing nucleotides positioned opposite the seed region of the antisense strand and modified nucleotides with reduced steric bulk, with pharmaceutical compositions and therapeutic methods for treating disease conditions also disclosed.
Methods and Compositions for Designing and Selecting TinyRNAs to Maximize Target Cleavage
USPTO published patent application US20260098266A1 by Kotaro NAKANISHI disclosing methods for designing and selecting tinyRNAs with guide RNA and Argonaute molecules for gene expression regulation in biotherapeutic and diagnostic applications. The application was filed April 1, 2024, and published April 9, 2026.
Antibody-Drug Conjugate Targeting GRP94 for Cancer Treatment
The USPTO published patent application US20260097129A1 for an antibody-drug conjugate comprising a drug and an antibody specifically binding to GRP94 (glucose-regulated protein 94) or an antigen-binding fragment thereof. The invention includes a pharmaceutical composition for treating cancer, leveraging strong internalization activity against GRP94-overexpressed carcinomas. The conjugate effectively inhibits growth of cetuximab-resistant colorectal cancer cell lines including HT29, HCT116, HCT8, and LoVo cells.
Liquid Formulation of Belumosudil - Kadmon Corporation
USPTO published patent application US20260097036A1 by Kadmon Corporation on April 9, 2026, covering liquid formulations comprising belumosudil, an immunosuppressive agent used in the treatment of subjects. The application was filed on September 20, 2023, under Application No. 19113101, with inventors Olivier Schueller, Galit Regev, Mark Beville, and Nazim Kanji. The published application includes claims directed to liquid pharmaceutical compositions of belumosudil and processes for preparing such formulations.
Floating IPN Drug Delivery System for Extended Release
USPTO published patent application US20260096986A1 covering pharmaceutical compositions with a floating interpenetrating polymer network (IPN) system for drug delivery. The compositions contain at least one IPN forming system, at least one drug, and at least one gas generating agent. Upon oral ingestion, the compositions form a floating IPN in situ that provides extended release of the entrapped drug for at least approximately 3 hours. The application was filed on December 12, 2025, under application number 19418060.
Kyoto University Pancreatic Endoderm Cell Production Method
USPTO published patent application US20260097083A1 by Kyoto University for a method of producing pancreatic endoderm cells involving culturing the cells in a medium containing a ROCK inhibitor combined with KGF and/or EGF. The application names inventors Kenji Osafune, Yu Hatano, and Azuma Kimura, with CPC classifications spanning A61K 35/39 and C12N 5/0676.
BlueRock Therapeutics LP Graft-Related Arrhythmia Treatment Patent Application
The USPTO published patent application US20260097012A1 by BlueRock Therapeutics LP on April 9, 2026, disclosing methods of treating or preventing graft-related arrhythmia in cardiac graft patients by administering combinations of anti-arrhythmic agents including amiodarone, metoprolol, ivabradine, and mexiletine. The application was originally filed on September 27, 2023. This published application makes the invention publicly available for examination and potential licensing or competitive intelligence purposes.